Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia

Blood

Volumn 101, Issue 5, 2003, Pages 2049-2053

  Ritgen, Matthias ^a   Lange, Alexandra ^b   Stilgenbauer, Stephan ^b   Döhner, Hartmut ^b   Bretscher, Christian ^b   Bosse, Heidi ^b   Stuhr, Ariane ^b   Kneba, Michael ^b   Dreger, Peter ^b  

^a I Dept of Medicine   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; MYELOABLATIVE AGENT; PRIMER DNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; DNA SEQUENCE; FEMALE; GENE MUTATION; GENE REARRANGEMENT; GERM LINE; HIGH RISK POPULATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE HOMOLOGY; STEM CELL TRANSPLANTATION;

EID: 0037370910     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1744     Document Type: Article

References (32)

1. Rozman C, Montserrat E, Chronic lymphocytic, leukemia. N Engl J Med. 1995;333:1052-1057.
2. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med, 2000;343:1910-1916.
3. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
4. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:18481-854.
5. Kröber A, Bühler A, Kenle D, et al. Analysis of VDJ rearrangement structure and VH mutation status in chronic lymphocytic leukemia [abstract]. Blood. 2001;98:358a.
6. H mutational status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-1416,
7. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993;82:1366-1376.
8. Dreger P, von Neuhoff N, Kuse R, et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance for cure? Br J Cancer. 1998;77:2291-2297.
9. Pavletic ZS, Biermann PJ, Vose JM, et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1999;9:1023-1026,
10. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia. 1998;12:1699-1707.
11. Michallet M, van Biezen A, Bandini G, et al. Analysis of prognostic factors on the outcome of autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia [abstract]. Blood. 2001;98:859a.
12. Esteve J, Montserrat E, Dreger P, et al. Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): outcome and prognostic factors after autologous and allogeneic transplants [abstract]. Blood. 2001;98:482a.
13. Dreger P, van Biezen A, Brand R, et al. Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EBMT experience [abstract]. Blood. 2000;96:482a.
14. Gribben JG, Neuberg D, Soiffer RJ, et al. Autologous versus allogeneic bone marrow transplantation for patients with poor prognosis CLL [abstract]. Blood. 1998;92:322a.
15. Dreger P, von Neuhoff N, Sonnen R, et al. Feasibility and efficacy of early autologous stem cell transplantation for poor-risk CLL [abstract]. Blood. 2000;96:483a.
16. Dreger P, Döhner H, Emmerich B, et al. A prospective multicenter study on early autologous stem cell transplantation in CLL (CLL3-study): first interim analysis [abstract]. Bone Marrow Transplant. 2000;25(suppl 1):S9.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
18. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62:567-575.
19. Döhner H, Stilgenbauer S, James MR, et al. 11 q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516-2522.
20. Van Dongen JJM, Langerak AW, San Miguel JF, et al. PCR-based clonality studies for early diagnosis of lymphoproliferative disorders: report of the BIOMED-2 concerted action [abstract]. Blood. 2001;98:543a.
21. Van Dongen JJM, Langerak AW, Bruggeman M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Leukemia. In press.
22. Linke B, Bolz I, Fayyazi A, et al. Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes. Leukemia. 1997;11:1055-1062.
23. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998;102:1515-1525.
24. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today. 1994;15:288-294.
25. Rohatiner AZS, Johnson PWM, Price CGA, et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994;12:1177-1184.
26. Freedman AS, Neuberg D, Mauch P, et al. Longterm follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999;94:3325-3333.
27. Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood. 1997;90:4212-4221.
28. Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J. 2000;1:87-94.
29. Flinn IW, O'Donell P, Noga SJ, et al. In vivo purging and adjuvant immunotherapy with rituximab during PBSC transplant for NHL [abstract]. Blood. 1998;92:648a.
30. Seyfarth B, Sonnen R, Zeis M, et al. Mantle cell lymphoma: promising results with upfront stem cel transplantation using the rituximab/TBI/CY high-dose regimen [abstract]. Blood. 2001;98:679a.
31. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, J Clin Oncol. 1998;16:2817-2824.
32. Dreger P, van Biezen A, Brand R, et al. Allogeneic stem cell transplantation (SCT) for chronic lymphocytic leukemia using intensity-reduced conditioning: an EBMT survey [abstract]. Blood. 2001;98:743a.